Autoimmunity and Thyroid Dysfunction During Sunitinib Treatment in Metastatic Renal Cell CarcinomaKaragöz, Bülent MD; Bilgi, Oğuz MD; Özgün, Alpaslan MD; Alacacoğlu, Ahmet MDı; Ylmaz, Bahattin MDı; Kandemir, Emin Gökhan MDAuthor Information From the Department of Medical Oncology, GATA Haydarpaҫsa Training Hospital, Istanbul, Turkey. Reprints: Bülent Karagöz, MD, Department of Medical Oncology, GATA Haydarpaҫsa Eğitim Hastanesi Tıbbi Onkoloji Kliniği, Haydarpaҫsa/İstanbul/Turkey. E-mail: [email protected] The Endocrinologist: September/October 2009 - Volume 19 - Issue 5 - pp 224-225 doi: 10.1097/TEN.0b013e3181b609b6 Buy Metrics Abstract Sunitinib, a multiple receptor tyrosine kinase inhibitor, is used in the treatment of renal cell carcinoma and gastrointestinal stromal tumors. Sunitinib-induced thyroid dysfunction has been reported; however, autoimmunity has not been thoroughly described during sunitinib treatment. In this report, we present a 57-year-old man with metastatic RCC who had transient subclinical hyperthyroidism and hypothyroidism during sunitinib therapy. He also developed anti nuclear antibody (speckled pattern) and antidouble stranded DNA positivity. © 2009 Lippincott Williams & Wilkins, Inc.